Methods and compositions for treating brain cancer
AssigneeGolden Biotechnology Corporation
InventorsSheng-Yung LIU, San-Bao HWANG, Wu-Che WEN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating brain cancer by cyclohexenone compounds.
Claims20
A method for the treatment of brain cancer comprising administering to a subject a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)m—CH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
A method of treating or preventing a cell proliferative disorder of the brain, comprising administering to a subject in need a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)m—CH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, wherein said cell proliferative disorder of the brain is treated or prevented.
A method for inhibiting brain cancer cells comprising contacting said cancer cells a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)m—CH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
Dependencies are inferred from the claim text.